Warfarin Sodium
**Warfarin** is a coumarin-derivative anticoagulant used primarily for the long-term treatment or prevention of thrombotic conditions in veterinary patients, such as cats, dogs, and horses. Due to its narrow therapeutic index, the potential for life-threatening hemorrhage, and the need for frequent and costly coagulation monitoring, its use in veterinary medicine is somewhat controversial and often reserved for specific cases where other anticoagulants are not feasible. **Clinical Pearls:** * Warfarin is administered as a racemic mixture of S(+) and R(-) enantiomers, with the S-enantiomer being significantly more potent. * Because it only inhibits the synthesis of *new* clotting factors, there is a characteristic **lag time of 2-5 days** before full anticoagulant effects are observed, as pre-existing circulating factors must first degrade. * Warfarin is the active ingredient in many first-generation anticoagulant rodenticides; toxicity presents identically to clinical overdose.
Mecanismo: Warfarin acts as an indirect anticoagulant by antagonizing Vitamin K. * It competitively inhibits the enzyme **Vitamin K epoxide reductase (VKORC1)**. * This inhibition prevents the conversion of inactive Vitamin K epoxide back into its active form (Vitamin K hydroquinone). * Active Vitamin K is an essential cofactor for the γ-carboxylation (activation) of **coagulation factors II, VII, IX, and X**, as well as the endogenous anticoagulant proteins C and S. * **Pathway:** VKORC1 inhibition → Depletion of active Vitamin K → Production of inactive, undercarboxylated clotting factors (PIVKA) → Prolonged clotting times and anticoagulation.
Dosificación por especie
- Adjunctive maintenance therapy for venous thrombosis with or without pulmonary thromboembolism (PTE) · 0.5 mg (total dose per cat) · PO · once daily · Initially, then adjusted to achieve a PT prolongation of 1.25 to 1.5 times the pretreatment value.
- Maintenance therapy for feline arterial thromboembolism · 0.06 to 0.09 mg/kg/day · PO · once daily · Heparinization is recommended during the first 5 to 7 days that warfarin is administered.
- Long-term thromboprophylaxis · 0.06-0.09 mg/kg per day · PO · once daily · Initially. Tablets should be crushed and mixed well due to unequal drug distribution. Overlap heparin and warfarin therapy by at least 4-5 days.
- Adjunctive therapy of thromboembolism · 0.25-0.5 mg (total dose) per cat · PO · once daily · Initially. Adjust dosage to prolong PT to twice normal value, or INR to be between 2-3. Overlap therapy with heparin.
- Cardiogenic arterial thromboembolism · 0.25-0.5 mg total dose per cat · PO · q24h · Heparin (150-250 Units/kg SC q8h) should be administered concurrently during the first 4-6 days. Target PT range is 1.3-1.6 times baseline, or INR 2.0-3.0.
- Adjunctive treatment of laminitis · 0.0198 mg/kg · PO · once daily · Monitor OSPT (one-step prothrombin time) until prolonged 2-4 seconds beyond baseline.
- Anticoagulant · Initially, 0.018 mg/kg PO once daily and increase dose by 20% every day until baseline PT is doubled. Final dose rates may be from 0.012 mg/kg to 0.57 mg/kg daily. · PO · once daily · ARCI UCGFS Class 5 Drug.
Vías de administración
Contraindicaciones
- Preexistent hemorrhagic tendencies or diseases
- Patients undergoing or contemplating eye or CNS surgery
- Major regional lumbar block anesthesia
- Surgery of large, open surfaces
- Active bleeding from the GI, respiratory, or GU tract
- Aneurysm
- Acute nephritis
- Cerebrovascular hemorrhage
- Blood dyscrasias
- Uncontrolled or malignant hypertension
- Hepatic insufficiency
- Pericardial effusion
- Pregnancy (Teratogenic - FDA Category X / Papich Class D)
- Visceral carcinomas
Efectos adversos
- Dose-related hemorrhage (primary adverse effect)
- Anemia
- Thrombocytopenia
- Weakness
- Hematomas and ecchymoses
- Epistaxis (nosebleeds)
- Hematemesis (vomiting blood)
- Hematuria (blood in urine)
- Melena (dark, tarry stools)
- Hematochezia (fresh blood in stools)
- Hemarthrosis (bleeding into joints)
- Hemothorax
- Intracranial hemorrhage
- Pericardial hemorrhage
- Death
Interacciones farmacológicas
- Acetaminophen, NSAIDs, Salicylates · May increase anticoagulant response (via protein displacement or platelet inhibition); increases bleeding risk.
- Fluoroquinolones, Macrolides (Azithromycin, Erythromycin), Chloramphenicol, Sulfonamides, Co-trimoxazole · May increase anticoagulant response (often via inhibition of hepatic metabolism).
- Cimetidine, Cisapride, Fluoxetine, Metronidazole, Sertraline · May increase anticoagulant response.
- Amiodarone, Allopurinol, Danazol, Diazoxide, Ethacrynic acid, Pentoxifylline, Propylthiouracil, Quinidine, Zafirlukast · May increase anticoagulant response.
- Anabolic Steroids, Thyroid Medications · May increase anticoagulant response.
- Heparin · Increases anticoagulant response; often used concurrently during the initial overlap phase but requires careful monitoring.
- Barbiturates (e.g., Phenobarbital), Rifampin, Griseofulvin · May decrease anticoagulant response (via induction of hepatic metabolizing enzymes).
- Corticosteroids, Estrogens, Mercaptopurine, Spironolactone, Sucralfate · May decrease anticoagulant response.
- Vitamin K · Directly antagonizes warfarin, decreasing its anticoagulant response (used as an antidote for overdose).
Monitoreo
- Prothrombin Time (PT) - Target usually 1.25 to 1.5x (or up to 2x) normal depending on protocol
- International Normalized Ratio (INR) - Target usually 2.0 to 3.0 (Note: not fully validated for veterinary patients)
- PIVKA (Proteins Induced by Vitamin K Antagonists) - May be more sensitive than PT
- Platelet counts and hematocrit (PCV)
- Occult blood in stool and urine
- Physical observations for bleeding (mucous membranes, bruising, epistaxis)
- Clinical efficacy (resolution/prevention of thromboembolism)
Sobredosis
Acute overdosages of warfarin may result in life-threatening hemorrhage. * **Toxic Doses:** In dogs and cats, single doses of 5-50 mg/kg have been associated with toxicity. Cumulative toxic doses are reported as 1-5 mg/kg for 5-15 days in dogs, and 1 mg/kg for 7 days in cats. * **Lag Time:** A lag time of 2-5 days may occur before clinical signs of toxicity manifest. Animals must be monitored closely during this period. * **Treatment:** If detected early, prevent absorption from the gut using standard decontamination protocols (emesis, activated charcoal). If clinical signs of bleeding are noted, treat with blood products (plasma/whole blood to replace active clotting factors) and **Vitamin K1 (phytonadione)**.
La referencia de fármacos de VetSheet está destinada a médicos veterinarios como apoyo a la decisión clínica; no sustituye el juicio profesional ni la información vigente del fabricante.